Q&A on the Johnson & Johnson COVID-19 vaccine with Mona Chitre, PharmD, Chief Pharmacy Officer and Vice President of Clinical Strategy and Innovation at Excellus BlueCross BlueShield

Posted on March 9, 2021

Dr. Chitre leads Excellus BlueCross BlueShield’s pharmacy strategy and is responsible for driving affordability, innovation and operational excellence. She completed her undergraduate and graduate training at Rutgers University and her post-doctoral primary care residency at the Buffalo VA Medical Center in Buffalo, New York.

Q: Dr. Chitre, the Johnson & Johnson (J&J) vaccine is the third COVID-19 vaccine being distributed in the U.S. Is it safe? Why do we need a third vaccine option?
A: All vaccines have the same goal – to protect us. The J&J vaccine was tested thousands of times to ensure safety and is authorized for use in the U.S. It’s important that everyone who wants the COVID-19 vaccine can receive it. In addition to the Moderna and Pfizer-BioNTech vaccines, the J&J vaccine is another way to help increase protection against the virus that causes COVID-19. Since all three vaccines are safe, the best vaccine is the one you have access to.

Q: How does the J&J vaccine differ from Moderna’s and Pfizer-BioNTech’s?
A: The J&J vaccine is a single dose which offers maximum protection quicker than Moderna’s and Pfizer-BioNTech’s vaccines. The J&J vaccine has proven to be 66% effective at preventing moderate to severe cases of COVID-19. With all three vaccine options, no fragment of the live virus is in the vaccine so the vaccine itself cannot make you sick with COVID-19.

Q: Should we be concerned with a less effective rate?
A: No, there is no need to be concerned. The only way to accurately compare the effectiveness of these vaccines is by direct comparison in head-to-head clinical trials, which did not happen across the three vaccine options. Testing took place in different regions, at different points in time, and with varying COVID-19 occurrences. It is best not to compare the effective rates between the vaccines.

The data proves that the J&J vaccine is 85% effective against severe COVID-19 cases, and 100% effective at preventing death from COVID-19. Based on the data, the J&J vaccine is a very safe and effective option.

Q: There is mention of a booster vaccine to help protect against the COVID-19 variants. What information is known or suggested about this?

A: Scientists are currently looking into if a booster dose is needed to address variants. It is emerging science at this time, but it is still recommended that you get your vaccine as soon as it is available for you.

Q: We know that vaccines were given to high-risk groups first. The data suggests that the number of deaths in nursing homes is going down by more than 60%. Do you feel this is because of the vaccine?
A: Absolutely. Nursing home residents were among the first people to receive the vaccine. The data shows how powerful the vaccines are against the virus, which is encouraging to hear. Reports like these make me so hopeful as the vaccines continue to rollout. I’m excited for my children to be reunited with their grandparents. I’m optimistic about the future.

Other Member News

June 3, 2026

Prototype to Production: De-Risking Polymer Parts

This session outlines a practical, non-promotional framework for moving polymer components from early prototypes to pilot builds and production-ready processes.

June 2, 2026

CNY Leadership Coach Ralph Simone Releases New Book, Slow Down to Go Faster: Living and Leading Intentionally

Readers will learn how to improve effectiveness and impact at work, but also to make life and leadership more joyful.

logo
June 1, 2026

Copurpose Brand + Strategy Chooses Downtown Syracuse for Next Chapter

The fast-growing marketing and AI firm has relocated to the historic Donohue Building at 316 S. Clinton St., placing the company in the heart of the city.

Central New York Community Foundation Names Kristi Eck as Chief Innovation & Growth Officer
June 1, 2026

Central New York Community Foundation Names Kristi Eck as Chief Innovation & Growth Officer

Eck brings more than 20 years of cross-sector leadership experience spanning higher education, workforce innovation, nonprofit leadership and public-private partnerships.

Thompson & Johnson Equipment Celebrates President & CEO Dave Schneckenburger’s 45-Year Anniversary
June 1, 2026

Thompson & Johnson Equipment Celebrates President & CEO Dave Schneckenburger’s 45-Year Anniversary

Dave Schneckenburger has dedicated nearly half a century to advancing the family-owned business while helping shape the future of the industry throughout New York State.

Nave Law Firm Recognizes YMCA of Central New York as June’s Nave’s Neighbor
June 1, 2026

Nave Law Firm Recognizes YMCA of Central New York as June’s Nave’s Neighbor

Nave Law Firm is proud to recognize the YMCA of Central New York as its June Nave’s Neighbor, celebrating the organization’s commitment to strengthening individuals, families, and communities across Central New York.

Longest Day 2026
May 29, 2026

Alzheimer's & Dementia Awareness Walk to Take Place at Oswego Farmers' Market June 18

Alzheimer's & Dementia Awareness Walk to Take Place at Oswego Farmers' Market June 18

New to Network graphic
May 29, 2026

Welcome to the CenterState CEO Network-June 2026

Welcome new members to the CenterState CEO Network.

ambassadors sfcu graphic
May 29, 2026

Ambassadors-CEO Insights June 2026

CenterState CEO Ambassadors welcome and recognize businesses celebrating grand openings, company anniversaries and other important milestones.